Contraception
Conditions
Interventions
-Single dose period: Single oral dose of LF111-4 mg tablets
-Repeated dose period: LF111-4 mg tablet is orally administered once a day for 24 days at intervals of 7 days or more after a single dose.
Sponsors
Kikuyama Ryoko
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: -Healthy premenopausal Japanese women aged 20 years or older and 35 years or younger at the time of informed consent. -Non-smokers (those who have not smoked within 6 months before obtaining informed consent). -Individuals who have a normal menstrual cycle (25 days to 38 days) including the menstrual period (bleeding from 3 days to 7 days) more than once before obtaining informed consent. -Individuals who agree on appropriate contraceptive methods other than oral contraceptives and intrauterine luteal hormone release system, including partners throughout the study.
Exclusion criteria
Exclusion criteria: -Individuals who have a positive pregnancy test at the time of screening. -Individuals who are pregnant (childbirth, miscarriage or abortion) or breastfed within 3 months before obtaining informed consent. -A cervical smear (cytology) at screening that was determined to be positive (other than negative (NILM) by Bethesda System 2014). -Individuals who currently have or have a history of thrombophlebitis, venous or arterial thromboembolic disease (thrombosis, pulmonary embolism, cerebral infarction, myocardial infarction). -Individuals with severe nervous system disease, digestive system disease, liver disease, or a problem taking the study drug. -Individuals assessed by the investigator as having clinically significant abnormalities in labolatory test at screening. -Individuals with renal or adrenal insufficiency or hepatic impairment. -Individuals with a history of intolerance to oral contraceptives. -Individuals who are or suspected of alcoholism, drug addiction. -Individuals who participated in another clinical trial within 16 weeks before administration of the investigational drug and received the investigational drug or who are currently participating in another clinical trial. -Personnel of the study site or family members of the investigator or subinvestigator. -Individuals who received 200 mL of blood within 4 weeks before administration of the investigational drug or 400 mL or more of blood within 16 weeks, or Individuals who donated blood components within 2 weeks before administration of the investigational drug. -Individuals known to be allergic to any of drug. -Individuals who regularly take the following drugs: Hormonal preparations (GnRH agonists, GnRH antagonists, estrogens, progestins, estogens/progestins) (all use in the last 6 months excluded) Agents known to induce hepatic drug-metabolizing enzymes (e.g. Rifampicin, dexamethasone, barbiturates, anticonvulsants, St. John's wort) Drugs known to inhibit CYP3A4 (e.g. Ketoconazole, verapamil, cimetidine, and macrolides) Drugs that raise serum potassium (e.g.Aldosterone antagonist,Potassium-sparing diuretics) -Individuals who consume a lot of xanthine-containing beverages (e.g. Five or more cups of coffee per day) -Individuals whose temperature at screening falls outside the range of 35-37.5 deg C. -ECGs at screening that are clinically abnormal. -Individuals with undiagnosed uterine bleeding. -Individuals with malignancy or a history of malignancy within 5 years before obtaining informed consent. -Individuals with a history of the following. -Individuals undergoing hysterectomy Gastrointestinal, hepatic, or renal disease that may affect the Pharmacokinetics of the drug Thromboembolism Cerebrovascular disorder Migraine with aura Adrenal insufficiency Pancreatitis Jaundice of pregnancy Surgery with general anesthesia within 3 months Pulmonary tuberculosis -Individuals who the investigator judges be inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Pharmacokinetics (DRSP plasma concentrations): -single dose Cmax,SD, AUC0-tau,SD, AUC0-72,SD, AUC0-inf,SD, Tmax,SD, t1/2,SD, MRT0-72,SD, MRT0-inf,SD, lambda z,SD, CL/FSD, Vd/FSD -repeated doses Cmax,SS, AUC0-tau,SS, AUC0-72,SS, AUC0-inf,SS, Tmax,SS, t1/2,SS, MRT0-inf,SS, lambda z,SS, CL/FSS, Vd/FSS, Ctrough, Robs(AUC), Robs(Cmax) 2) Pharmacodynamics (hormone levels): Progesterone, estradiol, LH, FSH 3) Safety: Clinical examination, vital signs, electrocardiography (Standard 12-lead ECG), laboratory tests, gynecological tests, Adverse events | — |
Contacts
Public ContactRyoko Kikuyama
ASKA Pharmaceutical Co., Ltd.
Outcome results
None listed